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infrequent dosage interval that permitted a
longer time of virus replication in the absence
of an adequate virus-static ganciclovir blood
concentration. However, the goal of CMV pro-
phylaxis is not to suppress CMV reactivation,
but to avoid the development of CMV disease
until a patient’s specific T-cells are capable of
coping with the virus [5]. As ganciclovir was
administered only three times a week by a
peripheral vein, outpatient treatment was poss-
ible. This allows cost savings and, in contrast to
an oral virus-static therapy, is independent of
the patient’s compliance. The suggested targeted
prophylactic approach is efficient, safe and easy
to perform in an outpatient clinic setting. Future
prophylactic therapies using new oral formula-
tions of antiviral agents [14] should be com-
pared to the regimen described in the present
study.
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A B S T R A C T
From January 2000 to June 2002, 24 Staphylococcus
aureus isolates were recovered from decubitus
ulcers of patients in a geriatric institution, of
which 17 (70.8%) were methicillin-resistant
S. aureus (MRSA). Antibiotic resistance and
DNA macrorestriction (pulsed-field gel electro-
phoresis; PFGE) patterns of the MRSA isolates
were compared with a collection of 161 MRSA
isolates from patients admitted to the institution’s
reference hospital. PFGE revealed the presence of
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five clonal types (found also in hospitalised
patients) among the 17 MRSA isolates. The
findings suggest nosocomial acquisition of the
MRSA strains by five patients, with subsequent
dissemination of the strains within the institution.
The high rate of MRSA highlights the need for
epidemiological analysis to control the dissemin-
ation of MRSA in long-term care facilities.
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The introduction of methicillin into clinical prac-
tice was followed almost immediately by the first
report in 1961 of methicillin-resistant Staphylococ-
cus aureus (MRSA) strains [1]. MRSA soon dis-
seminated through hospitals around the world
and, in the 1980s, became one of the most
important challenges in the treatment of nosoco-
mial infections [2]. In Europe, the proportion of
MRSA increased from < 1% in 1980 to 30% in
1991 [3]. In Spain, the first MRSA outbreaks were
detected simultaneously in 1988 in certain hospi-
tals in Madrid and Barcelona [4,5]. However,
MRSA was isolated seldom in Palma de Mallorca
until the first outbreak was detected in June 1999,
followed by endemicity.
The epidemiology of MRSA infections has
shown changes recently in both clinical and
microbiological aspects. The reservoir of MRSA
is apparently shifting from the hospital setting to
nursing homes [6,7], chronic-care facilities [8,9]
and spinal cord injury units [10]. The present
paper describes a molecular epidemiological
study of MRSA isolates recovered from decubitus
ulcers of geriatric patients in a large chronic-care
facility in Mallorca. The epidemiological related-
ness between these MRSA strains and those
isolated in the reference hospital for this geriatric
institution was also assessed.
The Hospital Universitario Son Dureta (HUSD)
is the reference tertiary hospital of the Balearic
Islands and has 980 beds. The Residencia de
Pensionistas La Bonanova has 552 beds and is the
main chronic-care facility of Mallorca. As part of
an epidemiological surveillance study, MRSA
isolates from geriatric patients with decubitus
ulcers admitted to the geriatric institution from
January 2000 to June 2002 were studied. Speci-
mens were collected with sterile swabs and sent
to the microbiology laboratory. S. aureus isolates
were identified by conventional methods [11].
Antimicrobial susceptibility testing was per-
formed by disk diffusion according to the guide-
lines of the National Committee for Clinical
Laboratory Standards [12]. Antibiotic disks (Ros-
co Laboratories, Taastrup, Denmark) tested were
oxacillin, penicillin, gentamicin, erythromycin,
clindamycin, ciprofloxacin, rifampicin, trimetho-
prim–sulphamethoxazole, mupirocin, fusidic
acid, teicoplanin and vancomycin. Additionally,
latex agglutination was performed to confirm the
presence of PBP2a (Slidex MRSA Detection kit;
bioMe´rieux, Marcy l’Etoile, France).
Clonal relatedness of MRSA isolates was deter-
mined by pulsed-field gel electrophoresis (PFGE).
Genomic DNA embedded in agarose blocks was
digested after bacterial lysis with SmaI. Chromo-
somal DNA fragments were separated using the
Chef-DR III system (Bio-Rad Laboratories, Rich-
mond, CA, USA), with 23 h at 6 V ⁄ cm2, and initial
and final pulse times of 1 s and 30 s, respectively.
PFGE band patterns were interpreted as described
previously [13]. For comparative purposes, a
collection of 161 previously typed MRSA isolates
from patients admitted to HUSD during 1999 and
2000 was used. Nomenclature for MRSA clones in
the present study was based on that established
for the previous collection.
During the 30-month study period, 24 S. aureus
isolates were recovered from the decubitus ulcers
of 24 different patients admitted to the chronic
care facility, of which 17 (70.8%) were MRSA. The
demographics and clinical characteristics of pa-
tients with MRSA are shown in Table 1. Ten
patients had been admitted previously to HUSD,
of whom five had been admitted since 1999 (the
date when the outbreak of MRSA began in
HUSD). MRSA was isolated in pure culture from
seven patients, and was associated with other
pathogens from ten patients. Associated patho-
gens comprised Pseudomonas aeruginosa (five
patients), Escherichia coli (three patients) and
Proteus mirabilis (two patients).
PFGE revealed the presence of four different
clones among the 17 MRSA isolates, one of which
had two subtypes. Clone A was found in eight
(47%) patients, clone B in one (6%) patient, clone
C2 in five (29.5%) patients, and clone E in three
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(17.5%) patients. Two subtypes of clone E were
found: clone E2 in two (11.5%) patients and clone
E1 in one (6%) patient (Fig. 1). All of these clones
were represented in the previous collection of 161
MRSA isolates from patients admitted to HUSD,
although in different proportions (clone A, 63%;
clone B, 20%; clone C2, 2.5%; and clone E, 1%).
None of these clones was related to the Iberian
clone described previously [14]. Interestingly, the
five different clonal types of MRSA were detected
in the five patients admitted to HUSD since 1999
(the time of the original outbreak).
All MRSA isolates were susceptible to vanco-
mycin, teicoplanin, trimethoprim–sulphameth-
oxazole, rifampicin and fusidic acid, but were
resistant to ciprofloxacin and erythromycin
(except one isolate). Resistance to clindamycin
(10.4%) and gentamicin (14.8%) was variable,
even among isolates from the same clone. Six of
the seven clindamycin-susceptible isolates
showed an MLSB-inducible phenotype. Clone A
had four different patterns of susceptibility, with
the most frequent (four patients) being character-
ised by resistance to erythromycin and clindamy-
cin, and susceptibility to gentamicin. Clone C2
had two different patterns, with the most frequent
(four patients) showing resistance to erythromy-
cin, and susceptibility to gentamicin and clinda-
mycin (with an MLSB-inducible phenotype).
S. aureus infection is a significant cause of
morbidity and mortality in elderly persons in
hospitals, in geriatric institutions, and in the
community [6]. S. aureus is the fourth most
common hospital-acquired pathogen in older
adults, following E. coli, P. aeruginosa and entero-
cocci, and it accounts for 9% of all nosocomial
infections in these patients [15]. In chronic care
facilities, rates of infection are similar to those
seen in hospitals [16]. Areas of chronic skin
breakdown, such as decubitus ulcers, are com-
mon in hospitalised patients and nursing home
residents. S. aureus is the microorganism isolated
most frequently in aspirates from such ulcers [17].
Age-related changes in skin, together with an
increased prevalence of peripheral vascular dis-
ease, diabetes mellitus and conditions that lead to
diminished mobility, are associated with risk of
skin infection in the elderly [16], as occurred in
the patients in the present study. MRSA coloni-
sation is common among nursing home residents
(8–46% of residents), although reports of docu-
mented MRSA infection are relatively uncommon
[16]. Limited studies suggest that most nursing
home residents acquire MRSA during a hospital
stay rather than in the nursing home [6]. It is
thought that transmission of MRSA between
nursing home residents is less frequent than in
hospitalised patients [6].
The present study found an unexpectedly high
rate of MRSA (70.8%) among S. aureus isolates
Fig. 1. SmaI PFGE macrorestriction patterns of the differ-
ent MRSA clonal types. Staphloccus aureus NCTC 8325 was
used as a molecular size marker. Lanes were obtained from
two different gels and normalised using the bands pro-
duced by the NCTC control strain.
Table 1. Characteristics of patients with decubitus ulcers
infected by MRSA
Characteristic n
Demographics
Mean age in years (range) 83 (75–94)
Sex (male ⁄ female) 5:12
Previous HUSD admissions
Never 7 (42%)
Before 1999 5 (29%)
Since 1999 5 (29%)
Underlying disease
Mobility limitationa 17 (100%)
Arterial hypertension 10 (59%)
Heart diseaseb 6 (35%)
Diabetes mellitus type 2 4 (23%)
Fever 8 (47%)
Number of ulcers
Sole 15 (88%)
Multiple 2 (12%)
Location
Foot 10 (59%)
Sacrum 7 (42%)
Hip 3 (18%)
Stage
Stage II (epidermis, dermis) 4 (23%)
Stage III (subcutaneous tissue) 8 (47%)
Stage IV (muscle, bone) 2 (12%)
Unknown 3 (18%)
Therapy
Topicalc 15 (88%)
Systemicd 10 (59%)
No treatment 2 (12%)
aIncluding dementia, ischaemic stroke, osteoarthritis, hip fracture and Parkinson’s
disease.
bIncluding heart failure, coronary artery disease, and atrial fibrillation.
cMupirocin (13 patients) or fusidic acid (two patients).
dTrimethoprim–sulphamethoxazole (five patients), gentamicin (two patients),
vancomycin (two patients), and teicoplanin (one patient).
HUSD, Hospital Universitario Son Dureta.
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from decubitus ulcers of patients in this geriatric
institution. Before 1999, no MRSA was detected in
residents of this facility, and only a few sporadic
cases were found in patients admitted to HUSD.
Five different clonal types of MRSA were detected
among the 17 patients of the geriatric institution,
with the five patients who had been admitted to
HUSD since 1999 each being infected by a
different clonal type of MRSA. Since all these
clones had been documented previously in
patients admitted to HUSD, it seems reasonable
to conclude that these patients acquired MRSA
strains during their hospitalisation period. The
fact that the other 12 patients had not been
hospitalised previously in HUSD suggests that
these MRSA clones may have spread subse-
quently between different patients within the
geriatric institution. The high rate of MRSA found
highlights the importance of epidemiological
analysis in controlling the dissemination of MRSA
in chronic care facilities, as in tertiary hospitals.
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A B S T R A C T
The combination of vancomycin and b-lactams is
often considered synergistic and has been recom-
mended for the treatment of glycopeptide-inter-
mediate Staphylococcus aureus (GISA) infections. In
this study, the combination of vancomycin or
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